{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:23:51Z","timestamp":1785767031572,"version":"3.56.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81301098"],"award-info":[{"award-number":["81301098"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangzhou Science and technology","award":["2014J4100100)"],"award-info":[{"award-number":["2014J4100100)"]}]},{"name":"Haizhu popularization of Science and technology project","award":["KP2010(T)-12"],"award-info":[{"award-number":["KP2010(T)-12"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.thromres.2014.06.023","type":"journal-article","created":{"date-parts":[[2014,7,5]],"date-time":"2014-07-05T15:15:16Z","timestamp":1404573316000},"page":"610-616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Genetic variations in the thrombin-activatable fibrinolysis inhibitor gene and risk of cardiovascular disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"134","author":[{"given":"Jian","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengke","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2014.06.023_bb0005","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1161\/CIR.0b013e31823ac046","article-title":"Heart disease and stroke statistics\u20132012 update: a report from the American Heart Association","volume":"125","author":"Roger","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.06.023_bb0010","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3109\/10408361003791520","article-title":"Genetic aspects of ischemic stroke: coagulation, homocysteine, and lipoprotein metabolism as potential risk factors","volume":"47","author":"Stankovic","year":"2010","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.thromres.2014.06.023_bb0015","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clinbiochem.2006.10.020","article-title":"Curiouser and curiouser: Recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles","volume":"40","author":"Boffa","year":"2007","journal-title":"Clin Biochem"},{"key":"10.1016\/j.thromres.2014.06.023_bb0020","first-page":"880","article-title":"Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level","volume":"89","author":"Santamaria","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2014.06.023_bb0025","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1046\/j.1365-2141.2003.04549.x","article-title":"Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system","volume":"122","author":"Zorio","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2014.06.023_bb0030","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1055\/s-0037-1613387","article-title":"Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence: The PRIME Study","volume":"89","author":"Morange","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.06.023_bb0035","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1111\/j.1538-7836.2005.01484.x","article-title":"High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke","volume":"3","author":"Leebeek","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.06.023_bb0040","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1161\/01.ATV.0000259354.93789.a6","article-title":"Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation","volume":"27","author":"Ladenvall","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.thromres.2014.06.023_bb0045","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1538-7836.2009.03350.x","article-title":"The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study","volume":"7","author":"De Bruijne","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.06.023_bb0050","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/1568006013337999","article-title":"Thrombin activable fibrinolysis inhibitor (TAFI): molecular genetics of an emerging potential risk factor for thrombotic disorders","volume":"1","author":"Boffa","year":"2001","journal-title":"Curr Drug Targets Cardiovasc Haematol Disord"},{"key":"10.1016\/j.thromres.2014.06.023_bb0055","first-page":"510","article-title":"Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis","volume":"86","author":"Franco","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2014.06.023_bb0060","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2006-01-008094","article-title":"Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study","volume":"108","author":"Frere","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.06.023_bb0065","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1161\/01.ATV.0000015445.22243.F4","article-title":"Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the North and South of Europe","volume":"22","author":"Juhan-Vague","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.thromres.2014.06.023_bb0070","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00277-008-0613-6","article-title":"Prothrombotic polymorphisms, mutations, and their association with pediatric non-cardioembolic stroke in Asian-Indian patients","volume":"88","author":"Biswas","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.thromres.2014.06.023_bb0075","first-page":"32","article-title":"Relationship between G505A polymorphism in the encoding region of thrombin-activated fibrinolysis inhibitor and cerebral infarction","volume":"9","author":"He","year":"2012","journal-title":"Chin J Cerebrovasc Dis"},{"key":"10.1016\/j.thromres.2014.06.023_bb0080","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1365-2141.2004.05219.x","article-title":"TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarction","volume":"127","author":"Akatsu","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2014.06.023_bb0085","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2008.002386","article-title":"Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men","volume":"94","author":"Meltzer","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2014.06.023_bb0090","first-page":"1017","article-title":"Study on the association of the gene polymorphism of thrombin activatable fibrinolysis inhibitor with coronary heart disease in Han population","volume":"30","author":"Jiang","year":"2007","journal-title":"Chin J Lab Med"},{"key":"10.1016\/j.thromres.2014.06.023_bb0095","first-page":"438","article-title":"Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymor-phisms of its encoding gene CPB2 in patients with coronary heart disease","volume":"25","author":"Xu","year":"2008","journal-title":"Chin J Med Genet"},{"key":"10.1016\/j.thromres.2014.06.023_bb0100","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.thromres.2009.07.004","article-title":"Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome","volume":"124","author":"Tassies","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2014.06.023_bb0105","first-page":"359","article-title":"Association between thrombin activatable fibrinolysis inhibitor encoding gene polymorphism and myocardial infarction","volume":"3","author":"Si","year":"2010","journal-title":"J Clin Hematol"},{"key":"10.1016\/j.thromres.2014.06.023_bb0110","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1160\/TH09-10-0682","article-title":"Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study","volume":"103","author":"Kozian","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.06.023_bb0115","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood.V99.5.1878a","article-title":"Thr325IIe polymorphism of the TAFI gene does not influence the risk of myocardial infarction","volume":"99","author":"Morange","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.06.023_bb0120","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/AC.66.4.2126597","article-title":"Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients","volume":"66","author":"Kamal","year":"2011","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.thromres.2014.06.023_bb0125","first-page":"13","article-title":"The Association between the Polymorphism(Thr325Ile)of CPB2 gene encoding TAFI and cerebral infarction","volume":"11","author":"Chen","year":"2004","journal-title":"Stroke Nerv Dis"},{"key":"10.1016\/j.thromres.2014.06.023_bb0130","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.thromres.2014.06.023_bb0135","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/(SICI)1097-0258(19960630)15:12<1237::AID-SIM301>3.0.CO;2-N","article-title":"Meta-analysis in the design and monitoring of clinical trials","volume":"15","author":"Dersimonian","year":"1996","journal-title":"Stat Med"},{"key":"10.1016\/j.thromres.2014.06.023_bb0140","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.thromres.2014.06.023_bb0145","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2014.06.023_bb0150","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2014.06.023_bb0155","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1161\/01.ATV.0000229694.97827.38","article-title":"Genetic risk for ischemic and hemorrhagic stroke","volume":"26","author":"Yamada","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.thromres.2014.06.023_bb0160","first-page":"45","article-title":"Variation in 24 clotting genes and risk of incident nonfatal myocardial infarction or ischemic stroke","volume":"115","author":"Smith","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.06.023_bb0165","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2141.2008.07384.x","article-title":"Thrombin activatable fibrinolysis inhibitor gene polymorphisms are associated with antigenic levels in the Asian-Indian population but may not be a risk for stroke","volume":"143","author":"Biswas","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2014.06.023_bb0170","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1055\/s-0037-1615353","article-title":"Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction\u2013the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction","volume":"80","author":"Scarabin","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.06.023_bb0175","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.thromres.2012.06.015","article-title":"Association of tissue plasminogen activator and plasminogen activator inhibitor polymorphism with myocardial infarction: a meta-analysis","volume":"130","author":"Gong","year":"2012","journal-title":"Thromb Res"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2014.06.023_bb0180","first-page":"78","article-title":"Alessi MCMorange PE Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity","volume":"32","author":"Juhan-Vague","year":"2000","journal-title":"Ann Med"},{"key":"10.1016\/j.thromres.2014.06.023_bb0185","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1182\/blood.V97.7.2053","article-title":"Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled","volume":"97","author":"Henry","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.06.023_bb0190","doi-asserted-by":"crossref","first-page":"68b","DOI":"10.1182\/blood.V98.6.1992","article-title":"Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and the prevalence of TAFI gene polymorphisms in patients with unstable angina pectoris","volume":"98","author":"Brouwers","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.06.023_bb0195","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/bmj.309.6965.1351","article-title":"Why sources of heterogeneity in meta-analysis should be investigated","volume":"309","author":"Thompson","year":"1994","journal-title":"BMJ"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814003491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814003491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T04:28:15Z","timestamp":1716956895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384814003491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0049384814003491"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2014.06.023","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic variations in the thrombin-activatable fibrinolysis inhibitor gene and risk of cardiovascular disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2014.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}